Real-world care for blood vessel and lymph vessel growths
Part of Genetic & congenital, Heart & circulation clinical trials.
This study looks at how people with abnormal blood vessel or lymph vessel growths are treated in everyday medical practice with certain medicines called mTOR, PI3K, and MEK inhibitors. It aims to learn more about how these treatments work in real life to help doctors make better decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a vascular anomaly (an abnormal growth of blood vessels or lymph vessels, including birthmarks, tumors, or malformations).
- You have been taking one of these medicines for at least 3 months continuously: an mTOR inhibitor (like sirolimus), a MEK inhibitor, or a PI3K inhibitor.
- You are not currently participating in another research study where you receive an experimental drug.
- You do not have other complex medical conditions such as certain rare genetic syndromes.
- Your medical records are complete enough for the study team to collect the needed information.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two targeted medicines for people with certain types of vascular malformations (abnormal blood vessels). If you have a slow-flow malformation, you may receive alpelisib; if you have a fast-flow malformation, you may receive mirdametinib. Genetic testing is needed to see if your malformation has a specific change that these drugs target.
This trial tests a new medicine, RLY-2608, that targets the specific genetic change (PIK3CA mutation) causing overgrowth conditions. It aims to see if the drug can slow or stop the growth of affected tissues.
This trial tests a pill called everolimus to see if it can shrink or control abnormal blood vessel growths (vascular anomalies) that have not responded to other treatments. It may offer a new option for patients aged 1 year and older.
This study collects extra blood (and sometimes tissue during procedures) to look for markers that can help doctors better understand vascular anomalies. It may not be a treatment, but it can improve future care by finding patterns linked to the condition.
This Phase 3 study tests whether sirolimus helps control complex vascular anomalies that have not responded to standard treatments. It also checks safety by monitoring blood tests, organ function, and overall health during treatment.
This trial tests different doses of sirolimus (a medication that slows cell growth) to find the best dose for treating cystic lymphatic malformations in children. It may help shrink the abnormal fluid-filled growths and improve symptoms.
Hear when a new Vascular Anomalies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.